title: Synaptic defects associated with s-inclusion body myositis are prevented by copper.
abstract: Sporadic-inclusion body myositis (s-IBM) is the most common skeletal muscle disorder to afflict the elderly, and is clinically characterized by skeletal muscle degeneration. Its progressive course leads to muscle weakness and wasting, resulting in severe disability. The exact pathogenesis of this disease is unknown and no effective treatment has yet been found. An intriguing aspect of s-IBM is that it shares several molecular abnormalities with Alzheimer's disease, including the accumulation of amyloid-β-peptide (Aβ). Both disorders affect homeostasis of the cytotoxic fragment Aβ(1-42) during aging, but they are clinically distinct diseases. The use of animals that mimic some characteristics of a disease has become important in the search to elucidate the molecular mechanisms underlying the pathogenesis. With the aim of analyzing Aβ-induced pathology and evaluating the consequences of modulating Aβ aggregation, we used Caenorhabditis elegans that express the Aβ human peptide in muscle cells as a model of s-IBM. Previous studies indicate that copper treatment increases the number and size of amyloid deposits in muscle cells, and is able to ameliorate the motility impairments in Aβ transgenic C. elegans. Our recent studies show that neuromuscular synaptic transmission is defective in animals that express the Aβ-peptide and suggest a specific defect at the nicotine acetylcholine receptors level. Biochemical analyses show that copper treatment increases the number of amyloid deposits but decreases Aβ-oligomers. Copper treatment improves motility, synaptic structure and function. Our results suggest that Aβ-oligomers are the toxic Aβ species that trigger neuromuscular junction dysfunction.
authors.affiliation: Center for Aging and Regeneration (CARE), Facultad de Ciencias Biológicas, Pontificia Universidad Católica de Chile, 8370003, Santiago, Chile. raldunate@santotomas.cl
authors.forename: R
authors.initials: R
authors.lastname: Aldunate
authors.forename: A N
authors.initials: AN
authors.lastname: Minniti
authors.forename: D
authors.initials: D
authors.lastname: Rebolledo
authors.forename: N C
authors.initials: NC
authors.lastname: Inestrosa
mesh_terms: D016229:Amyloid beta-Peptides / Q000378:metabolism; D000818:Animals; D030801:Animals, Genetically Modified; D017173:Caenorhabditis elegans; D003300:Copper / Q000627:therapeutic use*; D006801:Humans; D018979:Myositis, Inclusion Body / Q000188:drug therapy*; D009469:Neuromuscular Junction / Q000187:drug effects*
chemical_list: D016229:Amyloid beta-Peptides; D003300:Copper